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ABSTRACT 
Gut microbial β-glucuronidases are one of the key players in reactivating drug metabolites 
in the gut lumen. This reactivation can sometimes lead to dose-limiting side effects, such as 
severe diarrhea and intestinal bleeding1. Thus, understanding the structures and functions of 
these β-glucuronidases is critical for developing adjuvant therapies to alleviate the gut microbial 
β-glucuronidase-induced gastrointestinal toxicities2. However, the structural and functional 
diversities of gut microbial β-glucuronidase enzyme class are still poorly characterized. In this 
thesis, we describe three independent studies to understand these diversities. First, we studied 
the biochemical aspects of Streptococcus Agalactiae β-glucuronidase and Bacteroides dorei β-
glucuronidase and of structural aspects Bacteroides dorei β-glucuronidase inhibition. Next, we 
used loop swap mutants in an attempt to understand the function diversity caused by the 
extended active site loops. Last, we performed biochemical assays on a previously poorly 
characterized class of β-glucuronidase. Our works are a part of a collective effort to explore the 
gut microbial β-glucuronidase as an enzyme family. In the future, we can use our knowledge 
gained from these studies to further our knowledge on the interactions between the gut 
microbiota and drug metabolites and select β-glucuronidases as targets for inhibitor design. 
 
INTRODUCTION 
The human body is an intricate machinery with trillions of cells working interdependently 
to perform various biological functions. However, it is not just the human cells that reside on the 
human body: the human epithelial surfaces are home to the human microbiota, a collection of 
commensal microorganisms of which the total genome outnumbering the human genome 3:13. 
There are multiple microbiota communities in a human body, including skin microbiota, oral 
microbiota, and gut microbiota. The human gut microbiota, in particular, plays a major role in 
modulating human health by carrying out numerous biological processes critical for the human 
health4 (Figure 1). 
 
Figure 1: the major biological functions of the human gut microbiota 
 
One of the major ways that the gut microbiota impact human health is through becoming 
an integral part of host immune system. This is achieved in two folds. First, the normal gut 
microbiota plays a pivotal role in mucosal immunity by stimulating host production of 
immunoglobulin A-secreting plasma cells in lamina propria, intraepithelial lymphocytes, and 
microbicidal protein Angiogenin-45. Second, the gut microbiota can modulate host immunity.  
This is implicated in type I hypersensitivity, Alzheimer’s Disease, type I diabetes, and 
inflammatory bowel disease3, 6.  
The second major way that the gut microbiota impact human health is through key 
metabolite processing. The gut microbiota is responsible for the breakdown of complex 
carbohydrates to provide energy for the host, and this process accounts for at least 10% of the 
total available energy to the human body7. Other than carbohydrate fermentation, the gut 
microbiota synthesizes vitamins such as biotin, cobalamin, and niacin8. E. coli and other gut 
bacteria also synthesize a siderophore called enterobactin. Enterobactin was previously thought 
to be detrimental to human health as it is a genotoxin and its siderophore activity to only benefit 
the bacteria, not the host. However, recent studies show that the host can also use enterobactin 
for iron(III) intake9.  
The third major way that the gut microbiota influences human health is through endo- 
and xenobiotic processing. The gut microbiota can process endobiotics and xenobiotics, 
converting them into compounds that can either positively or negatively impact the human 
health. For example, the gut microbiota can produce estrogen by cleaving the glyosidic bond off 
estrogen glucuronides, an estrogen metabolite produced by the liver for secretion10, 11. Our group 
is interested in the gut microbial enzymes responsible for endo- and xenobiotics processing. 
 We were first interested in irinotecan metabolite processing Irinotecan is the first-line 
chemotherapy drug for patients with colorectal cancer (Figure 2). After irinotecan is administered, 
it is metabolized to the active metabolite SN-38 in the liver. Also in the liver, a glucuronic acid 
moiety is added to SN-38 at β-conformation to form SN-38 glucuronide (SN-38G) by UDP-
glucuronyltransferase to be marked for excretion. As a result, SN-38G reaches the 
gastrointestinal tract. Inside, the gut microbiota recognizes the glucuronic acid moiety and uses 
gut microbial β-glucuronidases (GUSs) to cleave the glyosidic bond in order to utilize the free 
glucuronic acid as a carbon source. The free SN-38 is then released to the gut lumen and causes 
gastrointestinal tract toxicity. This leads to dose-limiting side effects ranging from intestinal 
bleeding to massive diarrhea. Thus, we became interested in gut microbial GUSs, and we found 
that many other drug metabolites undergo similar processes in the gut lumen to cause 
gastrointestinal toxicity. For us, understanding the functions of gut microbial GUSs is critical to 
develop methods alleviate drug gastrointestinal toxicity6.  
 
Figure 2: drug glucuronidation in liver and drug glucuronide activation by microbial GUSs 
 
We first studied E. coli GUS (EcGUS) to characterize SN-38G processing and developed 
small molecule inhibitors to inhibit SN-38G by EcGUS. So far, we have developed two small 
molecule inhibitor series, Inhibitor 1 and UNC10201652. These inhibitors are specific to bacterial 
GUSs over human GUSs, as deficiencies in human GUSs cause the Sly Syndrome, a lethal 
lysosomal storage disease. Also, these inhibitors are not lethal to bacterial cells, so the GI tract 
microbiota composition is not altered by these inhibitors alone. These inhibitors exhibit high nM 
to low µM IC50 against EcGUS, and they can alleviate the GI side effects caused by irinotecan2, 12.  
We then mapped the primary sequence diversity of the gut microbial GUSs in order to 
better understand the causes of drug-induced gut toxicity. As the result, we learned that there 
are at least 279 unique GUS sequences in the GI tract microbiome13. We also learned that around 
50% of the unique GUS sequences have an extended loop region around the active site. Based 
on the primary sequence position of the loop and on the length of the loop, we categorized the 
GUSs based on 6 different subclasses: Loop 1 (L1), Loop 2 (L2), mini Loop 1 (mL1), mini Loop 2 
(mL2), mini Loop 1 and 2 (mL12), and no Loop (nL)13. We initially discovered that some L1 GUSs 
and process SN-38 glucuronide (SN-38G). The one mL1 GUS we then characterized, Bacteroides 
fragilis GUS also processes SN-38G, but with catalytic efficiency ~50% of active L1 GUSs14. Our 
small molecule inhibitors, however, are only effective against selected L1 GUSs. Thus, our long-
term goal is to develop inhibitors for non-L1 GUSs that are also important in drug glucuronide 
reactivation. To do this, we first need to fully understand the structural and functional diversity 
of the gut microbial GUS enzyme family. 
Here, we describe our work on this topic. First, we characterized Bacteroides dorei GUS 
biochemically, and we tested inhibition of Streptococcus Agalactiae GUS and Bacteroides dorei 
GUS by UNC10201652. Surprisingly, we found that Bacteroides dorei GUS is inhibited by 
UN10201652, so we attempted to identify the structural basis of this phenomenon. This work 
has been published in 201914. Then, to understand the functional diversity of GUSs, we developed 
loop swap mutants but found them to be catalytically inactive. Thus, we deployed biophysical 
analyses to understand the functions of these active site loops. Lastly, we performed kinetic 
assays on mL1 GUSs to investigate the functional diversity of this class of GUSs. Through these 
works, we showed that these GUSs exhibit drastically different kinetics and inhibitory parameters 
and provided some structural insights on these differences. By doing so, we furthered our 
understandings on the functional and structural diversity of gut microbial GUSs.  
 
MATERIALS AND METHODS 
1. Primary sequence analysis 
The primary sequences of GUSs of interests were obtained from UniProt (EMBL-EBI) or 
from our internal primary sequence database. Then, primary sequence alignments were 
performed by ClustalOmega (EMBL-EBI). For these alignments, information such as 
percent identity matrix were obtained from the built-in functions of ClustalOmega. 
 
2. Protein expression and purification 
The method was adopted from Kiernat et al 2019 and Pellock et al 201914, 15. In short, 
pLIC-plasmids containing his-tagged GUSs of interests were first transformed into BL21-
Gold E. coli cells in Miller lysogeny broth (LB) for overnight growth at 37°C. Afterwards, 
the media containing transformed E. coli cells were transferred to 100mL LB for a second 
round of overnight growth at 37°C. Then, the cells were transferred to 1.5L LB for 
incubation at 37°C. When the optical density of the cell media reached 0.6, 200µL 1M 
isopropyl β-D-thiogalactopyranoside was added to the LB to induce GUS protein 
expression, and the cells were incubated at 18°C overnight. The cells were pelleted by 
centrifugation at 4500×g for 20 minutes and stored at -80°C before purification. 
 
For protein purification, the cell pellets containing GUS of interest was first suspended in 
the lysis buffer (20mM potassium phosphate, 50mM imidazole, 500mM NaCl with one 
Roche EDTA-free protease tablet, 150µL DNAse1, and pinch lysozyme; pH7.4 for all except 
for UNC361-9 and Eubacterium spp. GUS (pH8.0)). The cells were then lysed via sonication, 
and the soluble content was subsequently separated from insoluble content via 
centrifugation at 17000×g at 4°C for 45 minutes. The supernatant was then filtered by 
syringe filtration, and the filtrate was then loaded onto nickel column with the nickel 
column loading buffer (20mM potassium phosphate, 50mM imidazole, 500mM NaCl; 
pH7.4 for all except for UNC361-9 and Eubacterium spp. GUS (pH8.0)) (General Electric 
ATKA FPLC system). Afterwards, the hexahistidine-tagged sample was then eluted from 
the nickel column with the wash buffer (20mM potassium phosphate, 500mM imidazole, 
500mM NaCl; same pH as loading buffer for each GUS). The largest sample peak from the 
affinity chromatography was then loaded onto Superdax 200 size exclusion 
chromatography column (General Electric ATKA FPLC system) and was eluted by super200 
column buffer (20mM HEPES, 50mM NaCl; pH same as previous buffers for each GUS). 
The largest sample peak was taken as the GUS of interest. If needed, the eluted GUS was 
concentrated in a concentration cassette tube by rounds of centrifugation at 3000×g at 
4°C. The GUS was then aliquoted and flashed frozen in liquid nitrogen. The aliquots were 
then stored in -80°C freezer. 
 
3. in vitro Kinetic assays 
In this thesis, p-nitrophenyl β-glucuronide (pNPG) and 4-methylumbelliferyl β-
glucuronide (4MUG) were used as substrates for in vitro GUS kinetic assays. The pNPG 
assay procedure was adapted from Biernat et al. 2019. In short, pNPG was purchased as 
a solid from Sigma Aldrich and was resuspended in water to form a 100mM solution. The 
assay was run in a 96-well, clear bottom assay plate (Costar) at 37°C. The final volume for 
each well in a reaction was 50µL, consisting of 10µL assay buffer (50mM sodium 
acetate(pH4-6.0)/50mM HEPES (pH6.5-7.4), 50mM NaCl, at GUS of interest optimal pH), 
10µL GUS (various concentrations), and 30µL pNPG (various concentrations).  Product 
formation was measured at 410nm with PHERAstar Plus Microplate reader (BMG 
Labtech). To determine the optimal pH of GUSs of interests, assays similar to 
aforementioned were performed, with the except of using 800µM pNPG at pH4.0-7.4. For 
assays run at pH6.0 or lower, reaction was quenched by 100µM 0.2M sodium bicarbonate 
at various time points and final product formation was measured by the plate reader.  For 
pH>6.5, quenching was not needed, and the product formation was monitored by the 
plate reader over time. The Michaelis-Menten kinetics module in SigmaPlot was used to 
calculate Km, kcat, and catalytic efficiency15. 
 
4MUG assay procedure was adopted from Pellock et al 2019. In short, reactions were 
performed a 96-well, clear bottom assay plate (Costar) at 37°C. 4MUG was purchased 
from Sigma Aldrich as a solid and was resuspended in 100% DMSO into 100mM solution. 
The final volume for each well in a reaction 50µL, consisting of 35µL water, 5µL assay 
buffer (25mM sodium acetate(pH4-6.0)/50mM HEPES (pH6.5-7.4), 50mM NaCl, at GUS of 
interest optimal pH), 5µL GUS (50nM, for 5nM final concentration unless otherwise 
noted), and 5µL 4MUG (varies concentrations). Reactions were initiated by addition of 
4MUG and were continuously monitored with excitation at 350nm and emission at 
450nm in PHERAstar Plus Microplate reader (BMG Labtech). Initial velocities from 
resultant data were fit by linear regression with a custom MATLAB program. In instances 
where Km, kcat, and catalytic efficiency were all reported, SigmaPlot 13.0 was used for 
perimeter calculations. In instances where only catalytic efficiency was reported, 
apparent kcat was first calculated, and catalytic efficiency was the slope of apparent kcat as 
a function of substrate concentration15. 
 
4. in vitro inhibition assay 
in vitro inhibition assay was as described in Biernat et. al 2019. In short, reactions 
consisting of 5µL GUS (15nM final for SaGUS, 150nM final for BdGUS), 5µL inhibitor 
(various concentrations), 30µL pNPG, and 10µL assay buffer (25mM NaCl, 25mM HEPES, 
pH6.5 or 7.4) were added into a Costar 96-well clear well plate. The reactions were 
initiated by pNPG addition, and the product formation was monitored by BMG Labtech 
PHERAstar Plus Microplate reader for 60 minutes. Due to the slow-binding nature of 
UNC10201652, IC50 was instead used as a measure for inhibitor efficacy. This was analyzed 
on SigmaPlot 13.0 by plotting the percent concentration as a function of log of inhibitor 
concentration and fitting with four-parameter logistic functions. The percent inhibition 
was calculated as: 
% inhibition = �1 −
Aexp − Abg
Amax − Abg
� × 100% 
Where Aexp is the end point absorbance at a particular inhibitor concentration, Amax  is 
the absorbance of the uninhibited reaction, and Abg is the background absorbance of the 
reaction15. 
 
5. Circular dichroism and melting temperature experiment 
The secondary structures and thermostabilities of WT EcGUS and loop swap mutants 
were compared by using circular dichroism and melting temperature experiment. 2.5µM 
GUS in CD buffer (10mM potassium phosphate, 100mM potassium fluoride; pH7.4) was 
loaded into 1-mm pathlength cuvette. Chirascan-plus instrument (Applied Photophysis 
Limited) was used to measure the circular dichroism of the GUSs. The melting profile of 
the samples were monitored at 211nm for all samples.  
 
6. Size-exclusion chromatography-multi-angle light scattering 
Size-exclusion chromatography-multiangle light scattering was used to determine the 
quaternary structure of WT EcGUS and loop swap mutants. The GUSs were analyzed on a 
Superdex 200 size exclusion column connected to Agilent FPLC system with Wyatt DAWN 
HELEOS II multi-angle light scattering instrument and Trax refractometer. 50µL of each 
GUSs (various concentrations) were injected, and SEC-MALS buffer (50mM HEPES, 
150mM NaCl, pH7.4) was used to elute the proteins. Light scattering and refractive index 
data were collected and analyzed using Wyatt ASTRA v. 6.1 software. 
 
7. Structural analysis 
All structural analyses were done on PyMOL. For docking experimental, molecules were 
manually docked into the active site of GUS. For hydrophobicity analyses, open-resource 
code provided the Protein Research Institute at Osaka University (Osaka, Japan) was used. 
 
Figure 3: the compounds of interests for this thesis. SN-38G (1) and diclofenac acyl glucuronide 
(DCF-G) (2) are the two biologically relevant compounds we are interested in, whereas pNPG (3) 
and 4MUG (4) were used as model substrates for (1) and (2). UNC10201652 (4-(8-(piperazin-1-
yl)-1,2,3,4-tetrahydro-[1,2,3]triazino[4',5':4,5]thieno[2,3-c]isoquinolin-5-yl)morpholine; (5)) is 
the gut microbial GUS inhibitor tested in this thesis.  
 
RESULTS 
NL GUS from Bacteroides dorei (BdGUS) is a poor hydrophobic small substrate processor 
Our landmark bioinformatics article published in 2017 indicated that BdGUS does not 
have an extended active site loop capping the active site pocket and predicted that BdGUS could 
not efficiently process SN-38G, but we had not yet obtained the kinetics parameters of BdGUS to 
test our prediction13. The chemical space of DCF-G and SN-38G is drastically different (Figure 3 
(1) and (2)). For instance, in SN-38, five rings are linked and forms two distinct conjugated rings 
systems, whereas DCF is essentially a secondary amine group with two aryl rings as substituents. 
However, these two compounds are both largely hydrophobic with the exception of glucuronic 
acid moiety. This enabled us to use a small, hydrophobic model substrate to conveniently test 
BdGUS kinetics when processing a hydrophobic compound.  
To do this, we used p-nitrophenyl β-glucuronide (pNPG, Figure 3 (3)) because the product 
of GUS pNPG processing, p-ntirophenyl (pNP-) absorbs light at 410nm if pH≥6.5. Thus, we could 
use UV/Vis spectroscopy to detect pNP- formation and calculate the kinetics of GUS of interest. 
Although pNP- does not absorb light when pH<6.5, we could relatively easily compensate for this 
by quenching the GUS processing reaction with 2M sodium bicarbonate at certain time points 
and obtain the concentrations of pNP- in quenched reaction mixture using the same 
spectrochemical method.  In the case of BdGUS, we tested the kinetics at its optimal pH (pH6.0). 
Our experimentally-obtained kinetic parameters of BdGUS confirmed our predictions. 
The catalytic efficiency of BdGUS (5.2×103 s-1M-1) is ~176-fold slower than that of EcGUS (9.2×105 
s-1M-1) (Figure 4A and B). Thus, BdGUS is not a good processor for pNPG and is also likely not a 
good processor for SN-38G and DCF-G. Nevertheless, we gained more insights into the kinetics 
of nL GUSs and functional diversity of the gut microbial GUS enzyme family. 
 
UNC10201652 can inhibit some GUSs, including BdGUS  
To counter the GI toxicity caused by DCF, we decided to test if our previously developed 
inhibitor, UNC10201652 (Figure 3 (5)), inhibit the novel GUSs discovered by the 2017 
bioinformatics study. Streptococcus Agalactiae GUS (SaGUS), was categorized as a L1 GUS. As we 
found that UNC10201652 inhibited EcGUS at high nanomolar level, we predicted that 
UNC10201652 could also inhibit SaGUS at similar inhibitor concentration13. In contrast, BdGUS, 
just as human GUS (HsGUS), does not have an extended active site loop capping the pocket. Then, 
our proposed UNC10201652 inhibition mechanism indicated that the extended active site loop 
needed to make contact with UNC10201652 to promote inhibitor binding to GUS active site 
pocket. Thus, we predicted that UNC10201652 could not inhibit BdGUS12, 13, 14.  
Our data confirmed our prediction on SaGUS inhibition by UNC10201652. The IC50 value 
of UNC10201652 against SaGUS was 450±30nM at pH6.5 and 133±3nM at pH7.5. However, to 
our surprise, BdGUS was also inhibited by UNC10201652 (IC50>250000nM at pH7.5), whereas 
HsGUS was not (Figure 4C)14. Although this finding is not clinically important, it remained an 
important scientific question to understand the basis of BdGUS inhibition by UNC10201652. 
 
Figure 4: the kinetics and inhibition of selected GUSs. A: the Michaelis-Menten kinetics of BdGUS. 
B: the kinetics parameter comparison between BdGUS and EcGUS. The catalytic efficiency of 
BdGUS (5.2×103 s-1M-1) is ~176-fold slower than that of EcGUS (9.2×105 s-1M-1). C: the IC50 values 
of EcGUS, SaGUS, and BdGUS against UNC10201652 (N. I.= not inhibited)15. 
  
BdGUS inhibition by UNC10201652 remains inconclusive 
In order to understand the structural basis of BdGUS inhibition by UNC10201652, we first 
used a residue-based approach. By docking UNC10201652 in BdGUS active site pocket in silico, 
we found that F456 and W458, two unique residues to BdGUS over HsGUS, may form π-stacking 
interactions with pyridine and triazine rings of UNC10201652. Moreover, a carbohydrate binding 
domain (CBM) loop unique to BdGUS over HsGUS rests above active site pocket opening, 
resembling the extended active site loop in L1 GUSs. (Figure 6A). We hypothesized that these 
unique features of BdGUS combined contribute to inhibition of BdGUS by UNC10201652. 
To test our hypothesis, we made three mutants: his-BdGUS F456A, his-BdGUS W458A, 
and his-BdGUS ΔCBM Loop and expressed the mutants in E. coli BL21G cell line. We then purified 
these mutants via affinity and size-exclusion chromatography. To examine the stability of these 
mutants, we ran SDS-PAGE for both WT and mutant BdGUS. BdGUS W358A and BdGUS ΔCBM 
Loop are of the same molecular weight as WT BdGUS, whereas BdGUS F456A showed signs of 
degradation (Figure 5). We then tested the kinetics and inhibitions of intact BdGUS mutants. 
However, we did not see the diminished inhibition as we expected (data not shown). 
 
Figure 5: SDS-PAGE gel of purified BdGUS mutants.  
 
We then decided to revisit the BdGUS structure (Figure 6A).  BdGUS forms a dimer, with 
the active site pockets facing outward. This configuration effectively exposes the pocket to 
solvent, including F456 and W458. As a result, F456 and W458 may be stabilizing each other, and 
this interaction may also be the stabilizing factor for the α-helix like motif of which F456 is the N-
terminal end, because the other regions of this motif are more hydrophilic and subject to 
denaturation by dissolution without F456-W458 interaction. F456A seems to have a more 
profound effect of W458A on BdGUS, most likely because F456 also forms an edge-to-face π-
stacking interaction with W423. The F456-W423 interaction may act as a staple for the F456-
W458 initiated α-helix like motif to the rest of BdGUS. Thus, losing F456-W423 interaction could 
cause global protein misfolding, making BdGUS F456A prone to degradation, as inferred in the 
FPLC chromatogram for BdGUS F456A and SDS-PAGE of BdGUS F456A. The W423-F456-W458 
interaction in BdGUS may also explain the cause for enhanced IC50 observed in BdGUS W558A 
mutant. Losing F456-W458 interaction is less likely to cause a global misfolding event because 
F456 and W458 are found on the same chain. However, loss of this π-stacking interaction 
increases the degree of freedom of α-helix like motif random walk. Thus, F456 and potentially 
W423 can be better positioned to interact with UNC10201652, thereby increasing its binding 
efficiency and in turn lowering IC50. Thus, we proposed that the π-stacking interactions among 
W423-F456-W458 may be instrumental for UNC10201652 binding to BdGUS, but F456-W458 
interaction found in WT BdGUS may hinder this process. However, our experimental results were 
inconclusive to test our new proposition. 
Because UNC10201652 is largely hydrophobic, we sought to explore the presence of a 
hydrophobic binding site on BdGUS for UNC10201652. To test this, we used an open-source 
python code to visualize the hydrophobicity of BdGUS residues. However, we found no such 
pockets. An encrypted pocket is unlikely to be found on BdGUS because GUSs do not go through 
conformational changes and are known to be structurally stiff and thermostable (Figure 6B). Thus, 
the mechanism of BdGUS inhibition by UNC10201652 remains inconclusive. 
 
Figure 6: the structural basis of BdGUS inhibition by UNC10201652 is inconclusive. A: The BdGUS 
(yellow) active site. The CBM loop (teal) W423, F456, and W458 (purple) are all unique to the 
BdGUS and may contribute to the inhibition of the enzyme by UNC10201652 (green). W423-
F456-W458 form hydrophobic interactions to stabilize the α-helix like motif. B: hydrophobicity 
map of BdGUS, with UNC10201652 docked. There is no observed hydrophobic caves inside 
BdGUS active site. 
 
Loop swap GUS mutants are catalytically inactive 
GUS is a diverse structurally and functionally diverse enzymes. Although the GUSs are all 
capable at cleaving glucuronic acid moiety, they do so at different rates, and they have different 
substrate preferences. Also, it became evident that UNC10201652 could only inhibit only a 
portion of L1 GUSs. We categorized the GUSs into different loop classes, but this categorization 
does not reflect the substrate preferences and differential kinetics of these GUSs13, 14, 15. Even 
within the same group of GUSs, the kinetics of these GUSs are drastically different when the same 
substrate is tested. One of the major differences among GUSs is their extended active site loops 
(Figure 7A-B). Because the catalytic residues of GUSs are conserved, we hypothesized that the 
identity of the extended active site loops affects GUS catalytic activities and inhibition by 
UNC10201652.  
 
Figure 7: L1 GUSs adopt highly variable active site loop structures. A: the overlay of the extended 
active site loops on EcGUS. B: the active site loop sequences of L1 GUSs used to make loop-swap 
mutants. 
 
To test this hypothesis, we designed three “loop swap” mutants by swapping the loops of 
SaGUS, Eubacterium eligens GUS (EeGUS), and Clostridium perfringens GUS (CpGUS) each with 
EcGUS loop. We reasoned that if the extended active site loop is responsible for modulating GUS 
kinetics, these loop swap GUSs should adopt the kinetics of loop donor GUSs. We used pNPG as 
our model substrate. To our surprise, these loop swap mutants have no significant catalytic 
activities (Figure 7A-C). We then used SDS-PAGE to check if the loop swap mutants were prone 
to degradation. Although we found that the mutants do not degrade in denaturing environments, 
we noticed that polymeric populations were prevalent in WT GUSs even with SDS denaturation, 
whereas all of the populations for loop swap mutants are monomers (Figure 8A). We reasoned 
that these loop swap mutants may have the same fold as WT EcGUS but are less thermostable. 
To test this hypothesis, we used circular dichroism to perform wavelength scans and melting 
temperature experiments for WT EcGUS and all loop swap mutants (Figure 8B-C). We found that 
while WT EcGUS and loop swap mutants have the same secondary structures, loop swap mutants 
melt at ~60˚C, whereas the melting point for EcGUS exceeds 94˚C (Figure 8C). We also used size 
exclusion chromatography-multiangle light scattering to determine the oligomerization state of 
WT EcGUS and all loop swap mutants and found that these enzymes are all tetramers (Figure 8C-
D). Our biophysical experiences confirmed our hypothesis that the loop swap mutants are less 
thermostable than WT EcGUS. However, the reason behind diminished activities of these loop 
swap GUSs remained to be unknown. 
 
Figure 8: loop-swap mutants are predicted to have the conserved fold but are shown to be 
inactive. A alignments of Phyre2 models of EcGUS-EeGUS loop hybrid (EcGUS-Ee loop; left, 
yellow), EcGUS-CpGUS loop hybrid (EcGUS-Cp loop; middle, orange), and EcGUS-SaGUS loop 
hybrid (EcGUS-Sa loop; right, purple) with WT EcGUS (cyan) show that the predicted loop swap 
mutants share the same tertiary structures with WT EcGUS; B pH screen with 100nM loop swap 
mutants (EcGUS-Ee loop is inactive) and 200µM 4-methylubelliferone β-glucuronide showed 
nM/s-scale rate; C kcat/Km of EcGUS-Sa loop is ~1000-fold slower than WT EcGUS. 
 
To answer this question, we used the open-access hydrophobicity visualization code to 
analysis EcGUS structure (Figure 8F-H). EcGUS forms a tetramer of which the center is the 
symmetry point of the structure (Figure 8F). The active site of EcGUS are outward-facing, with 
the active site within a protomer facing toward each other. This causes the active sites in a 
protomer to be in close proximity to each other (Figure 8G). The active site pockets of EcGUS is 
buried beneath the oligomerization interface. These features combined confine the active site of 
EcGUS (Figure 8G). Two largely hydrophobic loops from each monomer, one of which the 
extended active site loop used for loop class categorization, support the pocket by interacting 
with the base of EcGUS and provide the space needed for substrate entry and product exit (Figure 
8G-H). Because of these loops, the top hemisphere of EcGUS active site is largely hydrophobic 
fairly stable (Figure 8H). Thus, interrupting the hydrophobic loop-base interactions by loop 
swapping may destroy the stability of the hydrophobic hemisphere of EcGUS. The decreased 
active site pocket stability may lead to two possible outcomes. First, the instability can decrease 
the volume of the active site pocket and make substrate entry increasingly difficult. If this is true, 
the loop swap mutants cannot process any substrates. The second possible outcome is that the 
decreased stability causes the active site pocket to be more solvent-exposed. This means that 
while the loop swap mutants are poor processor for pNPG and other small hydrophobic 
substrates, these mutants may be better at processing hydrophilic substrates. While we have a 
deeper insight on the structural basis of the diminished kinetics of pNPG processing by loop swap 
mutants, more substrates need to be tested to understand the effect of loop swapping on EcGUS 
active site pocket. 
 
Figure 8: loop-swap mutants have similar secondary and quaternary structures as WT EcGUS but 
are less thermostable than WT EcGUS. A: Nonreducing SDS-PAGE gel of loop swap mutants. Lanes 
1-4: WT EcGUS, SaGUS, CpGUS, and EeGUS. Lanes 5-7: EcGUS-Sa loop, EcGUS-Cp loop, and 
EcGUS-Ee loop. Protein concentration is normalized at 36uM with pH 6.5 GUS buffer (25mM 
HEPES and 25mM NaOAC) before the addition of 3X Laemmli sample buffer and loading. The 
monomeric molecular weights of all GUSs are 70kDa. A 170kDa band exists for all WT bands, but 
not for loop swap GUSs. B: circular dichroism of WT EcGUS and loop-swap mutants show no 
differences in secondary structure. C: melting experiments of WT EcGUS and loop-swap mutants 
see a decrease of thermal stability of loop-swap mutants comparing to WT EcGUS. D: 
chromatogram and molar mass of WT EcGUS and loop-swap mutants. E: summary of D with 
monomeric mass of WT EcGUS and of loop-swap mutants and their respective oligomerization 
states. F-H: EcGUS hydrophobicity contour map. The Hydrophobicity gradient is shown at the 
bottom of the figure. Green=methionine, purple=catalytic glutamic acid. 
 
UNC361-9 forms aggregates during protein purification 
Previously, we have characterized Bacteroides fragilis mL1 GUS (BfGUS1) and Roseberia 
hominis mL1 GUS (RhGUS1)11, 13. Using primary sequence alignment tools, we found that BfGUS1 
and RhGUS1 lack similarity. Thus, we decided to characterize more mL1 GUSs to further our 
understandings on the functional diversity of these GUSs. 
We chose five novel mL1 GUSs based on the sequence similarity network: 
Facecalibacterium prausnitzii mL1 GUS (FpGUS4), Bacteroides massiliensis GUS (BmGUS), 
Eubacterium spp. GUS, and two GUSs from unknown species (UNC361-9 and UNC361-11, 
respectively). In order to predict the functions of these mL1 GUSs, we first aligned the sequences 
of these novel Ml1 GUSs with Ml1 GUSs BfGUS1 and RhGUS as well as known β-galactosideases 
(GalAse): Eisenbergiella tayi GalAse (EsGUS) and Fusicatenibacter saccharivorans GUS/GalAse 
hybrid (FsGUS/GalAse)16. We found that BmGUS and BfGUS1 share 70% primary sequence 
identity. We reasoned that BmGUS and BfGUS1 should possess similar biochemical functions. 
Otherwise, these GUSs share 18%-42% identity with each other, suggesting that they are unlikely 
to share similar substrate processing ability or substrate preferences.  
To study these GUSs, we expressed his-FpGUS4, his-BmGUS, his- Eubacterium spp. GUS, his-
UNC361-9, and his-UNC361-11 in E. coli BL21-Gold cell line for protein purification by fast protein 
liquid chromatography. All cell cultures were expressed nominally, and His-FpGUS4, his-BmGUS, 
his- Eubacterium spp. GUS and his-UNC361-11 were successfully purified by using Ni2+ column 
and Super200 size exclusion chromatography column. UNC361-9 was also purified by using the 
aforementioned columns. However, chromatogram of the size exclusion step shows that the 
majority of UNC361-9 population forms aggregates, as indicated by the wide band ranging from 
45mL-76mL column volume (Figure 9A). There are three other bands in the chromatogram, most 
likely indicating three possible non-aggregate oligomerization state UNC361-9 exhibits in a 
periplasm-free environment. Because the absorbance of pNP- at 410nm diminishes at pH<6.5, 
we used an analog 4-methylumbelliferyl glucuronide (4MUG), which is fluorescence-active across 
pH4.0-7.4, to examine the catalytic activities of the eluents corresponding the major peaks from 
pH4.0-7.0. However, we found that none of the eluents possess 4MUG processing abilities at any 
of the pH we tested (data not shown). It is unknown to us why UNC361-9 has a strong tendency 
to form aggregates in a cell-free environment. First, we reasoned that UNC361-9 is soluble in 
aqueous buffers used in the protein purification, as the protein was eluted during both FPLC steps. 
Then, we used SignalP-5.0 to predict if there are any signal peptides in UNC361-9 primary 
sequence that might cause aggregation to occur, but we did not find any. Previously, we showed 
that some GUSs bind to flavin mononucleotide (FMN) to stabilize the protein structure. We did 
not anticipate UNC361-9 to bind to FMN, as the enzyme in buffer solution is transparent, not 
yellow as is the color of FMN-binding GUSs. Nevertheless, we still checked if UNC361-9 contains 
motifs important for FMN binding16. As we expected, UNC361-9 lacks the tyrosine needed to 
form π-stacking interactions with the nucleotide. Therefore, UNC361-9 is unlikely to be an FMN-
binding GUS. One probable explanation is that UNC361-9 directly interacts with other 
macromolecules, such as molecular chaperones or functional proteins, to form stable 
heterooligomer. Without interactions with other subunits of this heterooligomer, UNC361-9 will 
aggregate. To test this theory, we can either use experimental methods to identify interactors of 
UNC361-9 in the native species, or we can use published protein-protein interaction databases 
to predict the possible interactions. The greatest obstacle we face to test this hypothesis is that 
UNC361-9 is of unknown species. For either of our approaches, we need species information to 
proceed. Thus, the reason for UNC361-9 aggregation remains inconclusive for now. 
 
mL1 GUSs exhibit diverse catalytic activities 
After successfully purifying his-FpGUS4, his-BmGUS, his-Eubacterium spp. GUS, and his-
UNC361-11, we tested their catalytic activities by using 4MUG and compared them with that of 
BfGUS1. We did not compare them to RhGUS1 because these novel GUSs share low primary 
sequence similarity with RhGUS1. We found that BmGUS and BfGUS1 have similar kcat/Km values 
and that FpGUS4 and UNC361-11 possess catalytic efficiency ~30-fold less than BmGUS and 
BfGUS1 (Figure 9B). Surprisingly, Eubacterium spp. GUS does not possess glyosidic bond cleavage 
activity of glucuronic acid from pH4.0 to pH7.4, even when [GUS] was increased to 100nM from 
5nM (not shown). Through this experiment, we gained a deeper understanding on the functional 
diversity of mL1 GUSs. 
 
Figure 9: characterization of novel mL1 GUSs. A: the FPLC size exclusion chromatogram of 
UNC361-9. B and C: catalytic efficiencies of active novel mL1 GUSs.  
 
DISCUSSIONS 
 The gut microbiota possesses diverse chemical processing capabilities. The gut microbial 
GUSs are great examples of this functional diversity. A family of at least 279 unique sequences, 
gut microbial GUSs has been shown to process small, largely hydrophobic substrates such as SN-
38G to largely charged oligosaccharides such as haparan sulfate13. In order to understand the 
importance of GUS in drug metabolite processing and to identify targets for novel GUS inhibitors, 
our works have focused on understanding the structural basis of this functional diversity. First, 
we sought to understand the molecular basis of GUS inhibition by UNC10201652, especially for 
BdGUS. Although our study was inconclusive, we still gained information about BdGUS structure 
and residues important for BdGUS stability14. Then, we characterized the biochemical and 
biophysical features of loop-swap GUS mutants and gained insights on the importance of the 
extended active site loop on GUS activity. Lastly, we expressed, purified, and characterized a 
panel of new mL1 GUSs. The knowledge we gained from these studies can be used to design small 
molecules as GUS inhibitors. 
 So far, we are only starting to uncover the complexity of the GUS enzyme family. In the 
gut microbiota only, there are at least 279 unique GUS sequences. Right now, we have 
characterized or are characterizing some of these GUSs, including BdGUS, SaGUS, FpGUS4, 
BmGUS, Eubacterium spp. GUS, UNC361-9, and UNC361-112, 11, 12, 13, 14, 15, 16,. Using biochemical 
and structural methods to characterize all of the members in the gut microbial GUS family would 
be extremely time consuming. Thus, we need novel methods to characterize or predict the 
biochemical properties of GUSs. So far, we have mainly used bioinformatics to select GUS 
sequences using a specific rubric and to construct sequence similarity networks on the gene 
products of these selected sequences. From assessing the clustering and comparing the edge 
lengths between GUS nodes on the sequence similarity network, we can make educated guesses 
on the biochemical and structural properties of novel GUSs13. However, we still need to conduct 
experiments to test our predictions, and these prediction tools do not tell us information about 
the preferred substrates of these GUSs. Thus, using more complex computational models to 
predict the kinetics and substrate preferences of these GUSs are necessary to reduce the 
workload of novel GUS characterization. To do this, we can compile information about GUS 
substrate processing for all substrates and chemical properties of these substrates. By correlating 
these data, we can find trends to GUS substrate preference and can use this information to better 
predict the substrate preferences of uncharacterized GUSs. Further, computational modeling can 
guide us to a better understand on the underlying mechanisms of difference in GUS substrate 
preferences. Our BdGUS inhibition study and loop swap study were attempts to experimentally 
study how a region of GUS affects its kinetics and inhibition, but our results were inconclusive in 
both occasions. By using computational modeling methods, such as molecular dynamics and 
molecular kinetics, can help us visualize and give direct explanations to the effects of altering the 
key residues identified in structural studies. 
 In our loop swap study, we noticed that the WT EcGUS has a high melting temperature 
(>94°C). GUSs consist of two immunoglobulin regions at the N-terminus, followed by a triose 
phosphate isomerase (TIM)-barrel domain. At the C-terminus, the GUSs consist 0-2 carbohydrate 
binding modules (CBMs) or domains of unknown functions (DUFs). Because the extended active 
site loop is within the TIM-barrel domain, we decided to investigate if some TIMs would also have 
similar melting temperatures. We found that Katebi and Jernigan have described that TIMs from 
thermophiles tend to form tetramers for the extra stability and that TIMs from mesophiles are 
likely to form dimers. EcGUS and other known L1 GUSs, also form tetramers17. This observation 
raises questions about the evolutionary origins of gut microbial GUSs. Indeed, our group have 
found that gut microbial GUSs have different oligomerization states, and our studies outlined in 
this thesis have indicated that GUSs have different substrate preferences. It is interesting to see 
if there is a difference in evolutionary origins between each class of GUSs and if this difference 
contributes to the differences in substrate preferences. Also, we have only tested GUSs catalytic 
activities at 37°C. As EcGUS has a high melting temperature, we can investigate EcGUS catalytic 
activity as a function of temperature. The absorbance of EcGUS changes at ~60°C. Although this 
does not signify a global denaturation event, it is possible that the immunoglobulin region of 
EcGUS becomes unfolded. We can use this strategy to investigate the function of the 
immunoglobulin region of EcGUS. By understanding these problems, we will be able to unveil the 
origins of GUSs and of the differences of substrate preferences.  
  Our work on novel mL1 GUSs is still ongoing as this thesis is written. So far, we have 
established that all novel mL1 GUSs except BmGUS are poor small hydrophobic substrate 
processors. It is possible that these mL1 GUSs are better processors for larger, more hydrophilic 
substrates. It is also possible that these mL1 GUSs are not glucuronide processors but are non-
GUS β-hexuronidases. We need to test this theory by using such substrates (such as haparan 
sulfate and p-ntirophenyl β-galactoside). We also need to use structural techniques to 
understand the molecular details of the active site pockets of these GUSs. Because BmGUS can 
process 4MUG with similar efficiency as BfGUS1, we need to test BmGUS against biologically 
important glucuronides, such as SN-38G, DCF-G, and serotonin glucuronide and find the 
importance of BmGUS in processing these substrates. By continuing to characterize these mL1 




In this thesis, we described our works on biochemical and biophysical characterization of 
BdGUS, SaGUS, loop swap mutants, and novel mL1 GUSs. First, we characterized BdGUS and 
SaGUS biochemically, and surprisingly, we found that BdGUS is inhibited by UN10201652, so we 
attempted to identify the structural basis of this phenomenon. Then, we developed loop swap 
mutants to understand the biochemical importance of the extended active site loop region but 
found them to be catalytically inactive. As a result, we used biophysical methods to understand 
the functions of these active site loops. Lastly, we characterized novel mL1 GUSs biochemically 
to investigate the functional diversity of this class of GUSs. Our work is instrumental in describing 
the functional and structural diversity of gut microbial GUS enzyme class. In the future, we can 
use our knowledge to further our understandings on the interactions between the gut microbiota 
and drug metabolites at and beyond GUSs. Also, we can refer to our insights gained in these 
studies to select non-L1 GUSs as targets for inhibitor development. 
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